Letters to the Editor |
Department of Internal Medicine, Catholic University, Rome, Italy
Institute of General Pathology, "Giovanni XXIII" Cancer Research Center, Catholic University, Rome, Italy
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
To the Editor:
We read with great interest the article by Wagner et al, in which the authors elegantly showed that membrane bound CD154 (CD40 ligand [L]) expressed by T-cells can effectively trigger CD40L expression by endothelial cells. More importantly, the authors demonstrated a functional activity of endothelium-associated CD40L, thus revealing a novel costimulatory activity in monocyteendothelial interactions.1 We have recently performed a series of experiments that aimed to study CD40L induction by endothelial cells, in particular assessing the consequences of the interactions between CD40L positive platelets with CD40 bearing endothelial cells.
CD40L expression was evaluated by flow cytometry in human intestinal microvascular endothelial cells (HIMEC) cultured alone, with resting and thrombin activated platelets, or stimulated with different activators, including interleukin (IL)-1ß, tumor necrosis factor (TNF)-
, and interferon (INF)-
. Functional CD40CD40L interactions were interrupted by using anti-CD40L specific antibodies, as reported.2
We found that CD40L was virtually absent in resting HIMEC (Figure A), and that all the potent proinflammatory molecules, such as IL-1ß, TNF-
, and INF-
, failed to induce CD40L expression, even though they were able to trigger HIMEC activation by upregulation of adhesion molecules (not shown). Resting platelets only slightly induced membrane bound endothelial CD40L (Figure B); in contrast, when endothelial cells were cultured with thrombin-positive CD40L platelets, HIMEC strongly upregulated CD40L expression (Figure C). Specificity of the CD40/CD40L pathway activation was demonstrated by platelet-CD40L blockade, as addressed by the strong inhibition induced by the use of the anti-CD40L antibodies (Figure
This article has been cited by other articles:
![]() |
R. J. Jaumdally, C. Varma, A. D. Blann, R. J. MacFadyen, and G. Y. H. Lip Platelet Activation in Coronary Artery Disease: Intracardiac vs Peripheral Venous Levels and the Effects of Angioplasty Chest, November 1, 2007; 132(5): 1532 - 1539. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Vowinkel, K. C. Wood, K. Y. Stokes, J. Russell, C. F. Krieglstein, and D. N. Granger Differential expression and regulation of murine CD40 in regional vascular beds Am J Physiol Heart Circ Physiol, February 1, 2006; 290(2): H631 - H639. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chakrabarti, S. Varghese, O. Vitseva, K. Tanriverdi, and J. E. Freedman CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2428 - 2434. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Danese, M Sans, and A Gasbarrini CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems Gut, June 1, 2005; 54(6): 891 - 892. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |